Manage episode 217604838 series 1452688
Guest: Scott Kopetz, MD, PhD, FACP
Guest: Luis Paz-Ares, MD, PhD
The presence of transforming growth factor-beta (TGF-β) in the tumor microenvironment plays a main role in limiting the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors. Not only does TGF-β suppress the normal anti-tumor action of natural killer cells and T cells, but it is also involved in many processes of cancer progression and metastasis, such as fibroid cap formation, epithelial-to-mesenchymal transition, and angiogenesis.
This panel will discuss the latest findings in the role of TGF-β in tumor formation and progression, as well as treatment advances that target PDL1 and TGF-β pathways simultaneously.
For more episodes in this series, visit ReachMD.com/IO.
135 episodes available. A new episode about every 33 days averaging 0 mins duration .